Schwierige Diagnose eines Makrophagen-Aktivierungs-Syndroms

• Literatur

• 1 Urien S, Bardin C, Bader-Meunier B. et al Anakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes. BMC Pharmacol Toxicol 2013; 14: 40.
• 2 Verbsky JW, White AJ. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol 2004; 31 (010) 2071-2075.
• 3 Lequerre T, Quartier P, Rosellini D. et al Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 2008; 67 (03) 302-308.
• 4 Hoshida Y, Xu JX, Fujita S. et al Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol 2007; 34 (02) 322-331.
• 5 Ichikawa A, Arakawa F, Kiyasu J. et al Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression. Eur J Haematol 2013; 91 (01) 20-28.
• 6 Ravelli A, Grom AA, Behrens EM, Cron RQ. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immun 2012; 13 (04) 289-298.